One of the companies to benefit is Boston's ViaCell. Of the 31 outfits pitching their plans at the Springboard 2000 venture-capital forum in Boston on Nov. 3, it is one of only two to snag financing so far. A cellular pharmaceuticals company that focuses on stem-cell technology, ViaCell received $48 million -- $8 million more than it asked for.
The company, which offers stem-cell banking and is developing synthetic stem cells, received this second round of funding from a syndicate of banks, equity funds, and investors, including Nomura International in London and a division of Deutsche Bank in Frankfurt. ViaCell sees its technology as promising major advances in the treatment of leukemia, a variety of genetic disorders and immune deficiencies, and in controlling rejection after organ transplants.
With such life-and-death technology at stake, how could a dot.com hope to compete? By Theresa Forsman in New York